Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Fate Therapeutics- Inc. (FATE)

11.86 -0.98 (-7.63%)

06-25 15:37

Open:

12.69

Pre. Close:

12.84

High:

12.88

Low:

11.67

Volume:

421,238

Market Cap:

627M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

13.146 - 13.234

13.234 - 13.307

Low:

12.315 - 12.399

12.399 - 12.468

Close:

12.715 - 12.854

12.854 - 12.969

Technical analysis  (as of: 2018-06-25 2:17:47 PM)

Overall:

      

Stoxline posted a SELL today, downgraded from higher rating. This stock seems to be ready for a new bearish move. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell now, downward move is expected.

Target:

Six months: 16.18     One year: 18.89

Support:

Support1: 11.48    Support2: 10.01

Resistance:

Resistance1: 13.85    Resistance2: 16.18

Pivot:

12.02

Moving Averages:

MA(5): 12.77     MA(20): 11.75

MA(100): 10.84     MA(250): 7.00

MACD:

MACD(12,26): 0.47     Signal(12,26,9): 0.39

%K %D:

%K(14,3): 66.91     %D(3): 77.98

RSI:

RSI(14): 54.10

52-Week:

High: 14.45  Low: 2.52  Change(%): 282.3

Average Vol(K):

3-Month: 64541  10-Days 118081

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
FATE has closed below upper band by 45.9%. Bollinger Bands are 22.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-05-10T22:11:06-04:00
Fate Therapeutics' (FATE) CEO Scott Wolchko on Q1 2018 Results - Earnings Call Transcript

2018-05-10T16:07:15-04:00
Fate Therapeutics misses by $0.05, misses on revenue

2018-05-09T10:35:34-04:00
Notable earnings after Thursday's close

2018-04-13T09:17:12-04:00
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned

2018-04-02T08:00:00-04:00
3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey

2018-03-30T08:00:00-04:00
Your Daily Pharma Scoop: Heron Offering, Sorrento Issues Letter To Shareholders, MediciNova Setback

2018-03-29T09:06:25-04:00
Fate Therapeutics' FATE-NK100 shows encouraging action in early-stage ovarian cancer study; shares ahead 5% premarket

2018-03-24T23:13:43-04:00
Week 13 Breakout Forecast: Short-Term Picks To Give You An Edge

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Bio Therapeutic Drugs

Shares Out. (M)

52.86

Shares Float (M)

52.30

% Held by Insiders

1.10

% Held by Institutions

71.00

Shares Short (K)

4389

Shares Short Prior Month (K)

4480

Stock Financials

EPS

-1.050

EPS Est. Current Year

-0.970

EPS Est. Next Year

-0.940

EPS Est. Next Quarter

-0.250

Forward EPS

-1.060

Book Value (p.s.)

10.640

PEG Ratio

Profit Margin

Operating Margin

-1125.65

Return on Assets (ttm)

-52.5

Return on Equity (ttm)

-72.9

Qtrly Rev. Growth

-0.1

Gross Profit (p.s.)

Sales Per Share

EBITDA (p.s.)

-0.364

Qtrly Earnings Growth

Operating Cash Flow (M)

-42.00

Levered Free Cash Flow (M)

-24.57

atoplab.com

Valuation

P/E

-11.54

P/E Growth Ratio

-0.06

P/BV

1.14

P/S

7118479872.00

P/CF

-15.25

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.